Back to Hematology
Hematologyv2022Evidence-Based

International Consensus Classification (ICC) Diagnostic Criteria for Primary Myelofibrosis (PMF)

Diagnoses primary myelofibrosis according to the International Consensus Classification (ICC) criteria published in 2022. This systematic diagnostic framework distinguishes between prefibrotic (early) and overt (fibrotic) stages of primary myelofibrosis using morphological, genetic, and clinical criteria. The ICC criteria refine the WHO classification system by providing better diagnostic specificity for myeloproliferative neoplasms. The diagnosis requires all three major criteria plus at least one minor criterion, confirmed in two consecutive determinations. This classification facilitates accurate diagnosis, appropriate staging, prognostic assessment, and treatment planning for patients with suspected primary myelofibrosis. The tool is particularly valuable for hematologists and pathologists in differentiating PMF from other myeloproliferative neoplasms and establishing precise diagnostic categorization.

Clinical Input Parameters

grade
Clinical Assessment
Awaiting Parameters
diagnosis result
—Points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The International Consensus Classification (ICC) Diagnostic Criteria for Primary Myelofibrosis (PMF) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Diagnosis requires ALL 3 major criteria (megakaryocytic proliferation, genetic clonality, exclusion of other MPNs) + ≥1 minor criterion (anemia, leukocytosis, splenomegaly, elevated LDH). Stage determined by fibrosis grade: Pre-PMF (grade 0-1), Overt PMF (grade 2-3).

Clinical Pearls & Practice Notes

  • The ICC criteria were published in 2022 as an updated international consensus for myeloid neoplasm classification
  • Diagnosis must be confirmed in two consecutive determinations to ensure accuracy
  • Pre-PMF distinguished from overt PMF primarily by bone marrow fibrosis grade
  • Prefibrotic PMF: fibrosis grade 0-1 with megakaryocytic proliferation and atypia
  • Overt PMF: fibrosis grade 2-3 with reticulin and/or collagen fibrosis
  • Genetic testing should use high-sensitivity assays (VAF ≥1%) for JAK2, CALR, and MPL mutations
  • JAK2 V617F mutation found in ~50-60% of PMF patients
  • CALR mutations found in ~20-25% of PMF patients
  • MPL mutations found in ~5-10% of PMF patients
  • Triple-negative PMF (no JAK2/CALR/MPL mutations) requires other clonal markers
  • Bone marrow biopsy essential for morphological assessment and fibrosis grading
  • Exclude reactive causes: infection, autoimmune disorders, metastatic cancer, drug-induced
  • Differential diagnosis includes ET, PV, CML, MDS, and secondary myelofibrosis
  • Anemia criterion: not attributable to nutritional deficiency, chronic disease, or other comorbidities
  • Leukocytosis threshold: ≥11 × 10^9/L white blood cell count
  • Splenomegaly: palpable on physical examination (imaging may supplement clinical assessment)
  • LDH elevation: above institutional upper limit of normal reference range
  • Risk stratification should follow diagnosis using IPSS-R, DIPSS, or MIPSS70 scoring systems
  • Regular monitoring for disease progression and transformation to acute leukemia required
  • Treatment decisions based on risk profile, symptoms, and patient-specific factors
  • Consider stem cell transplantation evaluation for eligible high-risk patients

Evidence & Literature Citations

  1. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 Sep 15;140(11):1200-1228. doi: 10.1182/blood.2022015850.
  2. Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014 Oct 16;124(16):2507-13. doi: 10.1182/blood-2014-05-579136.
  3. Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018 Feb 15;8(2):15. doi: 10.1038/s41408-018-0054-y.

Score Interpretation Ranges

Pre-PMF Diagnosed0 – 0 pts

Prefibrotic Primary Myelofibrosis

Overt PMF Diagnosed1 – 1 pts

Overt Fibrotic Primary Myelofibrosis

PMF Not Diagnosed2 – 2 pts

Diagnostic Criteria Not Met

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.